Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Personalized dosimetry for targeted radionuclide therapy: initial clinical experience from a case series at a tertiary cancer center (King Hussein Cancer Center).

Created on 12 Nov 2026

Authors

Serin Moghrabi, Saad Ruzzeh, Ahmed S Abdlkadir, Diyaa Juaidi, Manar W Alomary, Hongcheng Shi, Kalevi Kairemo, Mike Sathekge, Akram Al-Ibraheem

Published in

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of.... Nov 12, 2026. Epub Nov 12, 2026.

Abstract

Targeted radionuclide therapy (TRT) plays a pivotal role in managing differentiated thyroid cancer, neuroendocrine tumors, and metastatic castration-resistant prostate cancer. Personalized dosimetry quantifies absorbed radiation doses to tumors and organs at risk (OARs), enabling treatment individualization, improved therapeutic outcomes, and reduced toxicity.
This retrospective case series evaluated four patients treated at King Hussein Cancer Center (KHCC) between February 2024 and July 2025 with [131I]iodine, [177Lu]Lu-DOTATATE, or [177Lu] Lu-prostate-specific membrane antigen (PSMA). Patients were selected based on oligometastatic disease, adequate radiotracer uptake on baseline imaging, eligibility for radionuclide therapy, and absence of treatment contraindications. Dosimetry followed the medical internal radiation dose (MIRD) methodology with multi-timepoint imaging. Volumes of interest were segmented manually on post-therapy single photon emission computed tomography/computed tomography (SPECT/CT), time-activity curves were generated, and residence times were computed to estimate absorbed doses for tumor lesions and OARs. Treatment response was assessed using serial imaging and biochemical markers.
The cohort included two females (aged 9 and 45 years) and two males (aged 65 and 81 years). Substantial inter- and intra-patient variability in absorbed dose and response patterns was observed. The 45-year-old female received 180 mCi (6660 MBq) of [131I]iodine; skeletal metastases showed a broad dose range (~63-115 Gy), and the patient achieved a complete biochemical response. In the pediatric [177Lu]Lu-DOTATATE case, the patient received 75 mCi (2775 MBq) during the third treatment cycle; lesion dose (~8.8 Gy) and renal exposure remained within safe limits, despite asymmetric renal involvement. The 81-year-old male received 100 mCi (3700 MBq) of [177Lu]Lu-PSMA; a low lesion dose (~0.5 Gy) was observed, correlating with limited clinical benefit. The 65-year-old male received five cycles of 200 mCi (7400 MBq) [177Lu]Lu-PSMA each; marked lesion-specific heterogeneity was observed, with high-dose lesions regressing, whereas persistent PSMA-avid lesions suggested resistance. Across all patients, OAR doses remained below safety thresholds.
Personalized dosimetry is feasible in routine clinical practice and provides critical insights into dose-response relationships. It guides treatment optimization, identifies undertreated lesions, and helps maintain OAR safety, supporting its integration into TRT workflows to enhance therapeutic precision and outcomes.

PMID:
43018486
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement